Skip to main content
Premium Trial:

Request an Annual Quote

GenapSys Raises $8.5M of Targeted $13.6M

NEW YORK (GenomeWeb News) – DNA sequencing technologies startup GenapSys has raised $8.5 million of a target goal of $13.6 million, the company disclosed in a document recently filed with the US Securities and Exchange Commission.

The company said in its Form D that the amount raised is in the form of equity, and 11 investors participated in the raise.

Hesaam Esfandyarpour, GenapSys' founder and CEO, did not respond to requests seeking comment and it is unclear who the participants are in the private financing round. It also is unclear how the funds will be used.

Based in Redwood City, Calif., GenapSys was founded in 2010 and is developing a "cost-disruptive, easy-to-use genomic diagnostic platform" based on the company's Genius technology, it said on its website. The firm is in stealth mode and has provided few details about its technology.

Last year it received two grants for about $4 million in funding from the National Human Genome Research Institute to develop its sequencer. According to the grants' abstracts, GenapSys is working toward a platform that can sequence a genome at a consumables price of $50, generate average read lengths of up to 1,000 bases, and provide a "pre-assembly accuracy" of greater than 99.7 percent "with similar cost reduction and simplification for sample preparation," GenomeWeb Daily News sister publication In Sequence reported.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.